Denali Therapeutics Inc. Stock News

Shares of Denali Therapeutics Inc. rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. announced a $465 million equity investment as part of a collaboration on Denali

* DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic disease * Denali and collabora

Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease...

* Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19 * DNL758, discovere

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Seattle Seahawks linebacker will join investment firm Fuse Venture Partners to assist early-stage e-commerce companies.

BidaskClub cut shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports. Other equities research ana

Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™,

Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given an average rating of “Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. Four research ana

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Denali Therapeutics (NASDAQ:DNLI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. According to Za

Stocks Analysis by Zacks Investment Research covering: SPDR S&P 500, Union Pacific Corporation, KeyCorp, CarMax Inc. Read Zacks Investment Research's latest article on Investing.com

The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.

Denali Therapeutics Inc. (DNLI) announced that it is pausing clinical studies of DNL747, its neurological drug candidate for the treatment of Alzheimer’s disease and ALS, sending shares down some 7%

Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to.